Noa Bareli1, Roni Gat1,2, Victoria Makarov1,3, Ethel Siris4, Merav Fraenkel1,5, Uri Yoel6,7. 1. The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. 2. Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel. 3. Radiology Department, Soroka University Medical Center, Beer Sheva, Israel. 4. Division of Endocrinology, Columbia University Medical Center, New York, NY, USA. 5. Endocrinology Department, Soroka University Medical Center, Beer Sheva, Israel. 6. The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. uriy@bgu.ac.il. 7. Endocrinology Department, Soroka University Medical Center, Beer Sheva, Israel. uriy@bgu.ac.il.
Abstract
Bisphosphonates are common treatment for osteoporosis. Among patients admitted with hip fracture, atypical femoral fractures (AFF) were more prevalent in those who were treated with Bisphosphonates for five or more years. Five years of Bisphosphonates treatment may signify an increased risk for AFF, though the absolute risk remains very low. PURPOSE: Atypical femoral fractures (AFF) are a rare complication of bisphosphonate (BP) treatment. We evaluated the correlation between BP exposure and AFF risk among hip fracture patients. METHODS: This retrospective nested case-control study included patients over age 50 years, operated for osteoporotic hip fracture between July 2014 and November 2018, who attended our Fracture Liaison Service. We classified fracture radiographs and compared demographic, clinical, biochemical, and drug purchase data between patients with AFF and those with typical osteoporotic hip fracture (controls). To correct for the younger age of patients with AFF, we matched each case (AFF) with three controls according to age ([Formula: see text] 1 year) and sex and performed a conditional logistic regression model. RESULTS: Of 989 patients, 31 (3%) had AFF. Patients with AFF were younger than those with inter-trochanteric fractures (mean ± SD: 72.3 ± 10.3 vs. 80.2 ± 9.6 years, p < 0.001). Following matching, the mean Charlson's Comorbidity Index (CCI) was lower in the AFF than in the control group (2.9 ± 3.7 vs. 4.7 ± 4.2; p = 0.030) and a higher proportion of them were treated with BP for 5 years or more (58.1 vs. 16.0%; p < 0.001). Among patients admitted with hip fracture who were treated with BP for 5 years or more, the odds ratio of this fracture being atypical was significantly higher compared with no BP treatment (21.7; 95% CI-4.1-113.9). CONCLUSIONS: Patients with AFF compared to typical hip fractures showed better baseline medical conditions irrespective of their younger age. Five years of BP treatment may be associated with an increased risk for AFF, though the absolute risk remains very low.
Bisphosphonates are common treatment for osteoporosis. Among patients admitted with hip fracture, atypical femoral fractures (AFF) were more prevalent in those who were treated with Bisphosphonates for five or more years. Five years of Bisphosphonates treatment may signify an increased risk for AFF, though the absolute risk remains very low. PURPOSE: Atypical femoral fractures (AFF) are a rare complication of bisphosphonate (BP) treatment. We evaluated the correlation between BP exposure and AFF risk among hip fracture patients. METHODS: This retrospective nested case-control study included patients over age 50 years, operated for osteoporotic hip fracture between July 2014 and November 2018, who attended our Fracture Liaison Service. We classified fracture radiographs and compared demographic, clinical, biochemical, and drug purchase data between patients with AFF and those with typical osteoporotic hip fracture (controls). To correct for the younger age of patients with AFF, we matched each case (AFF) with three controls according to age ([Formula: see text] 1 year) and sex and performed a conditional logistic regression model. RESULTS: Of 989 patients, 31 (3%) had AFF. Patients with AFF were younger than those with inter-trochanteric fractures (mean ± SD: 72.3 ± 10.3 vs. 80.2 ± 9.6 years, p < 0.001). Following matching, the mean Charlson's Comorbidity Index (CCI) was lower in the AFF than in the control group (2.9 ± 3.7 vs. 4.7 ± 4.2; p = 0.030) and a higher proportion of them were treated with BP for 5 years or more (58.1 vs. 16.0%; p < 0.001). Among patients admitted with hip fracture who were treated with BP for 5 years or more, the odds ratio of this fracture being atypical was significantly higher compared with no BP treatment (21.7; 95% CI-4.1-113.9). CONCLUSIONS: Patients with AFF compared to typical hip fractures showed better baseline medical conditions irrespective of their younger age. Five years of BP treatment may be associated with an increased risk for AFF, though the absolute risk remains very low.
Authors: Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte Journal: J Bone Miner Res Date: 2013-10-01 Impact factor: 6.741
Authors: Richard M Dell; Annette L Adams; Denise F Greene; Tadashi T Funahashi; Stuart L Silverman; Eric O Eisemon; Hui Zhou; Raoul J Burchette; Susan M Ott Journal: J Bone Miner Res Date: 2012-12 Impact factor: 6.741
Authors: Steven Boonen; Jean-Yves Reginster; Jean-Marc Kaufman; Kurt Lippuner; Jose Zanchetta; Bente Langdahl; Rene Rizzoli; Stanley Lipschitz; Hans Peter Dimai; Richard Witvrouw; Erik Eriksen; Kim Brixen; Luis Russo; Frank Claessens; Philemon Papanastasiou; Oscar Antunez; Guoqin Su; Christina Bucci-Rechtweg; Josef Hruska; Elodie Incera; Dirk Vanderschueren; Eric Orwoll Journal: N Engl J Med Date: 2012-11-01 Impact factor: 91.245
Authors: Ashley A Lloyd; Bernd Gludovatz; Christoph Riedel; Emma A Luengo; Rehan Saiyed; Eric Marty; Dean G Lorich; Joseph M Lane; Robert O Ritchie; Björn Busse; Eve Donnelly Journal: Proc Natl Acad Sci U S A Date: 2017-07-31 Impact factor: 11.205